AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16679090 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (group I)
Number of subjects: 48
Study 16679090 — intervention group
Group type: COMPARATOR
Intervention: Control (group II)
Number of subjects: 48
Study 15596193 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg every 84 days
Number of subjects: 247
Study 15596193 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg every 28 days
Number of subjects: 247
Study 11413430 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 60
Study 11413430 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicar
Number of subjects: 60
Study 11413430 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 9210777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga therapy
Number of subjects: 61
Study 9210777 — intervention group
Group type: COMPARATOR
Intervention: Traditional group psychotherapy
Number of subjects: 61
Study 8682922 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) using e-PTFE membrane
Number of subjects: 28
Study 8682922 — intervention group
Group type: COMPARATOR
Intervention: Flap debridement alone (Control)
Number of subjects: 28
Study 1978164 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin A every six months
Number of subjects: 15775
Study 1978164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15775
Study 90859 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous metronidazole
Number of subjects: 83
Study 90859 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (control)
Number of subjects: 83
Study 31639775 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic implantation to the dorsum of the tongue (PB)
Number of subjects: 100
Study 31639775 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue scraping (TS)
Number of subjects: 100
Study 31639775 — intervention group
Group type: COMPARATOR
Intervention: Mouthwash alone (MW)
Number of subjects: 100
Study 28662043 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance program plus annual MDA if warranted
Number of subjects: 52
Study 28662043 — intervention group
Group type: COMPARATOR
Intervention: Annual MDA alone if warranted
Number of subjects: 52
Study 27649551 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent 50 Gy (in 4 fractions) to liver
Number of subjects: 35
Study 27649551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential 50 Gy (in 4 fractions) to liver
Number of subjects: 35
Study 27649551 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent 50 Gy (in 4 fractions) to lung
Number of subjects: 35
Study 27649551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential 50 Gy (in 4 fractions) to lung
Number of subjects: 35
Study 27649551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential 60 Gy (in 10 fractions) to lung or liver
Number of subjects: 35
Study 23650297 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (family-focused and clinician-focused)
Number of subjects: 22486
Study 23650297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22486
Study 23650297 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-focused intervention
Number of subjects: 22486
Study 21232669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg infusion for 10 min, followed by a 15-min observation, and a second infusion of 2 mg/kg if still in AF)
Number of subjects: 254
Study 21232669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 254
Study 21232669 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone (60-min infusion of 5 mg/kg followed by a maintenance infusion of 50 mg over an additional 60 min)
Number of subjects: 254
Study 21232669 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 254
Study 19143902 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 2 g orally twice daily for 1 day and clobetasol gel 0.05% twice daily for 3 days
Number of subjects: 42
Study 19143902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17250931 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vaccinia virus Ankara (MVA) with DNA priming
Number of subjects: 192
Study 17250931 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vaccinia virus Ankara (MVA) alone
Number of subjects: 192
Study 17250931 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 192
Study 15093954 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg) plus Pindolol (5 mg)
Number of subjects: 6
Study 15093954 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine plus Placebo
Number of subjects: 6
Study 11428178 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild yam cream
Number of subjects: 23
Study 11428178 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 23
Study 9679620 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (15 mg once daily)
Number of subjects: 62
Study 9679620 — intervention group
Group type: COMPARATOR
Intervention: Captopril (2-4 times daily)
Number of subjects: 62
Study 1793422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy (CBGT) for a period of 3 months
Number of subjects: 91
Study 1793422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group therapy (CBGT)
Number of subjects: 91
Study 6871067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuelin Depot 350 mg with antacid
Number of subjects: 12
Study 6871067 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur 300 mg with antacid
Number of subjects: 12
Study 6871067 — intervention group
Group type: COMPARATOR
Intervention: Nuelin Depot 350 mg without antacid
Number of subjects: 12
Study 6871067 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur 300 mg without antacid
Number of subjects: 12
Study 30775145 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of oral cephalexin
Number of subjects: 115
Study 30775145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 30111262 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mastoid electrical stimulator (PMES)
Number of subjects: 140
Study 30111262 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo control)
Number of subjects: 140
Study 30111262 — intervention group
Group type: EXPERIMENTAL
Intervention: PMES
Number of subjects: 140
Study 26782276 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nutrition program with immune modulating formulae (enriched with arginine, omega-3 fatty acids and nucleotides) for ten days
Number of subjects: 58
Study 26782276 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (Control)
Number of subjects: 58
Study 26782276 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nutrition program with immune modulating formulae
Number of subjects: 58
Study 25084967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index dietary intervention
Number of subjects: 542
Study 25084967 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 542
Study 25084967 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal gestational weight gain
Number of subjects: 542
Study 25084967 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoking status
Number of subjects: 542
Study 25084967 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age, smoking status, maternal pre-pregnancy arm circumference, percentage energy from saturated fat in late pregnancy, postprandial glucose at 28 weeks gestation, trimester 2 glycaemic load
Number of subjects: 542
Study 22829849 — intervention group
Group type: EXPERIMENTAL
Intervention: Single allogenic mesenchymal stem cells transplantation (MSCT) at a dose of one million MSCs per kilogram of body weight.
Number of subjects: 58
Study 22829849 — intervention group
Group type: COMPARATOR
Intervention: Double allogenic mesenchymal stem cells transplantation (MSCT).
Number of subjects: 58
Study 22829849 — intervention group
Group type: EXPERIMENTAL
Intervention: Single MSCT.
Number of subjects: 58
Study 22829849 — intervention group
Group type: COMPARATOR
Intervention: Double MSCT.
Number of subjects: 58
Study 18823912 — intervention group
Group type: EXPERIMENTAL
Intervention: Barcode medication administration (BCMA) system
Number of subjects: 958
Study 17147514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic handgrip (IHG) at 40% MVC followed by post-exercise circulatory occlusion (PECO)
Number of subjects: 10
Study 17147514 — intervention group
Group type: COMPARATOR
Intervention: Non-ischaemic handgrip (HG) at 40% MVC
Number of subjects: 10
Study 15939922 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI (irinotecan 180 mg/m(2) on day 1 with LV 100 mg/m(2) and FU 400 mg/m(2) bolus, FU 600 mg/m(2) infusion)
Number of subjects: 360
Study 15939922 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 (oxaliplatin 85 mg/m(2) on day 1 with LV5FU2 regimen)
Number of subjects: 360
Study 12028212 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed written materials
Number of subjects: 735
Study 12028212 — intervention group
Group type: COMPARATOR
Intervention: Written materials plus a videotape
Number of subjects: 735
Study 9608782 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (Mexico City)
Number of subjects: 71
Study 9608782 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (Tula, Hidalgo)
Number of subjects: 71
Study 9608782 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (Contepec, Michoacán)
Number of subjects: 71
Study 7630245 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum androgen blockade (MAB) - castration plus prolonged use of an antiandrogen (flutamide, cyproterone acetate, or nilutamide)
Number of subjects: 5710
Study 7630245 — intervention group
Group type: COMPARATOR
Intervention: Conventional castration (surgical or medical)
Number of subjects: 5710
Study 7630245 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum androgen blockade (MAB)
Number of subjects: 5710
Study 7630245 — intervention group
Group type: COMPARATOR
Intervention: Conventional castration
Number of subjects: 5710
Study 7630245 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall MAB trials
Number of subjects: 5710
Study 2258895 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 30
Study 2258895 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 30
Study 6102454 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of the internal mammary artery into the left ventricular myocardium
Number of subjects: 146
Study 6102454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 146
Study 30348460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg on day 0, 10 mg on day 1, 5 mg on day 2)
Number of subjects: 76
Study 30348460 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment only)
Number of subjects: 76
Study 30348460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 76
Study 30348460 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study 28756278 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet (D)
Number of subjects: 429
Study 28756278 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss diet plus exercise (D + E)
Number of subjects: 429
Study 28756278 — intervention group
Group type: COMPARATOR
Intervention: Exercise control group (E)
Number of subjects: 429
Study 28756278 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 429
Study 26231498 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (moderate dose)
Number of subjects: 50
Study 26231498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24494286 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus warm needling therapy (EA + WN)
Number of subjects: 93
Study 24494286 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 93
Study 24494286 — intervention group
Group type: COMPARATOR
Intervention: Warm needling therapy (WN)
Number of subjects: 93
Study 21482928 — intervention group
Group type: EXPERIMENTAL
Intervention: GRN+ FTLD-TDP
Number of subjects: 97
Study 21482928 — intervention group
Group type: COMPARATOR
Intervention: GRN- FTLD-TDP
Number of subjects: 97
Study 19399980 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interruption of sedative infusions
Number of subjects: 97
Study 19399980 — intervention group
Group type: COMPARATOR
Intervention: Sedation as directed by the intensive care unit team (control)
Number of subjects: 97
Study 17531920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (nicotine content, 0.9 mg)
Number of subjects: 52
Study 14745677 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin surface-modified PMMA intraocular lenses (HSM-IOLs)
Number of subjects: 18
Study 14745677 — intervention group
Group type: COMPARATOR
Intervention: Foldable hydrophobic acrylic intraocular lenses (Acrysof-IOLs)
Number of subjects: 18
Study 11550111 — intervention group
Group type: EXPERIMENTAL
Intervention: temocapril
Number of subjects: 46
Study 11550111 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 46
Study 11550111 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 9491830 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumatic spacer
Number of subjects: 12
Study 9491830 — intervention group
Group type: EXPERIMENTAL
Intervention: NebuChamber spacer
Number of subjects: 12
Study 9491830 — intervention group
Group type: COMPARATOR
Intervention: Sidestream nebuliser
Number of subjects: 12
Study 7868850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 34
Study 7868850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 3583070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 50
Study 30334920 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT (12 weeks, cycle ergometer, progressive volume 6-12 series, intensity 140%-170% lactate threshold)
Number of subjects: 20
Study 30334920 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 28052885 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified young-child formula (YCF) (1.2 mg Fe/100 mL; 1.7 μg vitamin D/100 mL)
Number of subjects: 318
Study 28052885 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified young-child formula (YCF)
Number of subjects: 318
Study 28052885 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified cow milk (CM) (0.02 mg Fe/100 mL; no vitamin D)
Number of subjects: 318
Study 25439429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2.0 mg every 8 weeks (2q8)
Number of subjects: 2419
Study 25439429 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg every 4 weeks (0.5q4)
Number of subjects: 2419
Study 22360365 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilink Sprint (Ivoclar Vivadent)
Number of subjects: 40
Study 22360365 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (3M ESPE, USA)
Number of subjects: 40
Study 22360365 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Cem (GC, Japan)
Number of subjects: 40
Study 22360365 — intervention group
Group type: COMPARATOR
Intervention: Variolink II (Ivoclar Vivadent)
Number of subjects: 40
Study 20060790 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg cefuroxime tablet
Number of subjects: 36
Study 17106277 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP1452 alone
Number of subjects: 330
Study 17106277 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP1452 plus rgp120
Number of subjects: 330
Study 17106277 — intervention group
Group type: COMPARATOR
Intervention: vCP1452 alone and rgp120
Number of subjects: 330
Study 17106277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 15501926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (acute: bolus 0.06; drip 0.02 g/kg fat-free mass)
Number of subjects: 22
Study 15501926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (chronic: 500 mg/day for 30 days)
Number of subjects: 22
Study 15501926 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 22
Study 11772423 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone replacement therapy
Number of subjects: 50
Study 11772423 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy
Number of subjects: 50
Study 9788685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg with sustained-release pseudoephedrine (PSE) 120 mg
Number of subjects: 24
Study 9788685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7658780 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release melatonin (2 mg per night for 3 weeks)
Number of subjects: 12
Study 7658780 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 weeks)
Number of subjects: 12
Study 2501598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (transdermal administration via Nitroderm TTS 10 for 48 hours)
Number of subjects: 7
Study 2501598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 57507 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 350
Study 31233972 — intervention group
Group type: EXPERIMENTAL
Intervention: National MMT training
Number of subjects: 418
Study 31233972 — intervention group
Group type: COMPARATOR
Intervention: Stigmatizing attitudes towards PWUD
Number of subjects: 418
Study 29444522 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication alone
Number of subjects: 168
Study 29444522 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (antipsychotic medication + psychosocial intervention)
Number of subjects: 168
Study 29444522 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 168
Study 27502589 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEMg (β-carotene, ascorbic acid, dl-α-tocopherol acetate, magnesium) administered twice daily for approximately 3 months
Number of subjects: 140
Study 27502589 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 140
Study 27502589 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEMg treatment
Number of subjects: 140
Study 25003274 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (5 cmH2O) during exercise tests at 75% of peak work rate of incremental test (IT)
Number of subjects: 7
Study 25003274 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (5 cmH2O) at rest and during exercise tests at 50% of peak work rate of IT
Number of subjects: 7
Study 23479993 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA7 (omeprazole 0.04 g/day, clarithromycin 1 g/day, amoxicillin 2 g/day for 7 days)
Number of subjects: 128
Study 23479993 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA14 (same drugs for 14 days)
Number of subjects: 128
Study 23479993 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA7L1 (same drugs for 7 days + glucosaminylmuramyldipeptide 0.001 g/day for 1 day)
Number of subjects: 128
Study 23479993 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA7L10 (same drugs for 7 days + glucosaminylmuramyldipeptide 0.01 g/day for 10 days)
Number of subjects: 128
Study 23479993 — intervention group
Group type: COMPARATOR
Intervention: OCA7 with glucosaminylmuramyldipeptide 0.001 g/day
Number of subjects: 128
Study 20580870 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide 20 microg/day
Number of subjects: 207
Study 20580870 — intervention group
Group type: COMPARATOR
Intervention: placebo-teriparatide
Number of subjects: 207
Study 17081536 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% vaginal P gel (90 mg) administered daily
Number of subjects: 285
Study 17081536 — intervention group
Group type: COMPARATOR
Intervention: Utrogestan vaginal capsules (2 x 100 mg) administered three times daily
Number of subjects: 285
Study 17081536 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% vaginal P gel
Number of subjects: 285
Study 17081536 — intervention group
Group type: COMPARATOR
Intervention: Utrogestan vaginal capsules
Number of subjects: 285
Study 16128936 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 7 days (E20-7d)
Number of subjects: 450
Study 16128936 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg b.i.d.) with the same antibiotics for 7 days (E40-7d)
Number of subjects: 450
Study 16128936 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg b.i.d.) with the same antibiotics for 10 days (E40-10d)
Number of subjects: 450
Study 12113566 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon 5
Number of subjects: 54
Study 12113566 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 54
Study 10465924 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg hydromorphone s.c.
Number of subjects: 60
Study 10465924 — intervention group
Group type: COMPARATOR
Intervention: 50 mg meperidine i.m.
Number of subjects: 60
Study 8576333 — intervention group
Group type: EXPERIMENTAL
Intervention: BacT/Alert Aerobic FAN bottle
Number of subjects: 483
Study 8576333 — intervention group
Group type: COMPARATOR
Intervention: BACTEC Plus Aerobic/F bottle
Number of subjects: 483
Study 2259918 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC I (high-dose cytarabine 3 g/m2/12 h on day 1 + mitoxantrone 10 mg/m2/d on days 2 and 3)
Number of subjects: 31
Study 2259918 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC II (high-dose cytarabine 3 g/m2/12 h on days 1 and 2 + mitoxantrone 10 mg/m2/d on days 2 and 3) with rhGM‐CSF
Number of subjects: 31
Study 2259918 — intervention group
Group type: COMPARATOR
Intervention: NOAC II (high-dose cytarabine 3 g/m2/12 h on days 1 and 2 + mitoxantrone 10 mg/m2/d on days 2 and 3) without rhGM‐CSF
Number of subjects: 31
Study 2259918 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC II with rhGM‐CSF
Number of subjects: 31